PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Given Consensus Rating of “Hold” by Analysts

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has been assigned a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $40.8182.

A number of research analysts have commented on the stock. Oppenheimer reissued a “market perform” rating on shares of PROCEPT BioRobotics in a research report on Thursday, February 26th. Wells Fargo & Company lowered their price target on shares of PROCEPT BioRobotics from $51.00 to $34.00 and set an “overweight” rating on the stock in a report on Thursday, February 26th. Leerink Partners lowered their price target on shares of PROCEPT BioRobotics from $55.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Thursday, January 22nd. Finally, Jefferies Financial Group cut shares of PROCEPT BioRobotics from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 26th.

Insider Buying and Selling

In related news, Director Antal Rohit Desai bought 98,699 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was bought at an average cost of $24.55 per share, for a total transaction of $2,423,060.45. Following the purchase, the director directly owned 426,262 shares of the company’s stock, valued at approximately $10,464,732.10. This trade represents a 30.13% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Waters sold 6,721 shares of PROCEPT BioRobotics stock in a transaction that occurred on Friday, March 6th. The stock was sold at an average price of $23.70, for a total transaction of $159,287.70. Following the completion of the sale, the executive vice president owned 152,264 shares of the company’s stock, valued at $3,608,656.80. This trade represents a 4.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders purchased 426,262 shares of company stock worth $10,483,091 and sold 23,229 shares worth $573,466. 6.60% of the stock is owned by company insiders.

Institutional Trading of PROCEPT BioRobotics

Institutional investors have recently bought and sold shares of the stock. JTC Employer Solutions Trustee Ltd acquired a new stake in PROCEPT BioRobotics in the 3rd quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd lifted its stake in PROCEPT BioRobotics by 436.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 917 shares of the company’s stock valued at $29,000 after acquiring an additional 746 shares during the period. Center for Financial Planning Inc. acquired a new stake in PROCEPT BioRobotics during the 4th quarter valued at approximately $40,000. US Bancorp DE lifted its stake in PROCEPT BioRobotics by 175.7% during the 3rd quarter. US Bancorp DE now owns 1,693 shares of the company’s stock valued at $60,000 after acquiring an additional 1,079 shares during the period. Finally, Cache Advisors LLC acquired a new stake in PROCEPT BioRobotics during the 1st quarter valued at approximately $42,000. 89.46% of the stock is currently owned by institutional investors and hedge funds.

PROCEPT BioRobotics Trading Up 1.4%

NASDAQ PRCT opened at $25.11 on Thursday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 5.77 and a current ratio of 6.85. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -14.68 and a beta of 0.94. The company’s 50-day simple moving average is $25.68 and its two-hundred day simple moving average is $29.95. PROCEPT BioRobotics has a one year low of $19.35 and a one year high of $66.85.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its earnings results on Wednesday, February 25th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.21). The business had revenue of $76.38 million for the quarter, compared to analysts’ expectations of $93.70 million. PROCEPT BioRobotics had a negative net margin of 31.02% and a negative return on equity of 25.13%. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the business posted ($0.35) EPS. Equities analysts forecast that PROCEPT BioRobotics will post -1.58 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.